GlassScriptPhysician profile
Lindsay S Holtz
NPI 1386965150
$9,806.86
in general payments reported to CMS, 2019-2025
40 companies · $1,651 in 2025
The $1,651 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,360 · 2020: $605 · 2021: $744 · 2022: $1,305 · 2023: $2,193 · 2024: $1,948 · 2025: $1,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,720 · Education: $72.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,719.91 |
| Education | $72.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,541.54 | 2019-2025 | |
| Amgen INC. | $1,303.04 | 2019-2025 | Enbrel, Tavneos, Evenity |
| Pfizer INC. | $1,147.41 | 2019-2025 | |
| Ucb, INC. | $981.76 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $735.02 | 2019-2025 | |
| Janssen Biotech, INC. | $714.96 | 2019-2025 | Tremfya, Remicade, Simponi Aria |
| Lilly USA, LLC | $546.42 | 2019-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $464.11 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $297.25 | 2019-2025 | Benlysta |
| Genentech USA, INC. | $275.16 | 2019-2025 | Actemra, Gazyva |
| Astrazeneca Pharmaceuticals LP | $257.03 | 2021-2024 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $228.31 | 2021-2023 | Acthar |
| Cumberland Pharmaceuticals, INC. | $122.80 | 2022-2023 | Reditrex |
| Sandoz INC. | $110.24 | 2023-2025 | Hyrimoz |
| Organon LLC | $100.72 | 2023-2025 | Renflexis, Hadlima |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Holtz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.